The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDA’s data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities.
Gary Lawrence
FDA’s Expedited Drug Programs [PDF ebook]
Analysis, Postmarket Monitoring and Industry Guidance
FDA’s Expedited Drug Programs [PDF ebook]
Analysis, Postmarket Monitoring and Industry Guidance
购买此电子书可免费获赠一本!
格式 PDF ● 网页 113 ● ISBN 9781634857734 ● 编辑 Gary Lawrence ● 出版者 Nova Science Publishers ● 发布时间 2016 ● 下载 3 时 ● 货币 EUR ● ID 7227061 ● 复制保护 Adobe DRM
需要具备DRM功能的电子书阅读器